TRIP11

Across TCGA pan-cancer cohorts, TRIP11 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TRIP11 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher TRIP11 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TRIP11 expression acts as an unfavorable survival marker, although some lineages such as COAD and PDAC show a favorable association.

COAD, PDAC, and LUAD are the cancer types where TRIP11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Tertile	II,III,IV	1.000	0.907	.034	42	view →
PDAC	OS	Quartile	III,IV	0.948	0.227	.006	13	view →
LUAD	OS	Median	II,III,IV	0.893	0.453	.026	4	view →
CCRCC	OS	Median	All	0.706	0.919	.040	3	view →
HNSC	DFS	Quartile	III,IV	0.381	0.639	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TRIP11–COAD (DFS)

Open the COAD breakdown →